Article Text

Download PDFPDF

Journal club
Bronchoalveolar lavage-directed therapy does not affect prevalence of Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis
  1. H Haja Mydin
  1. Correspondence to Dr Helmy Haja Mydin, Department of Respiratory Medicine, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, UK; enidan{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Early Pseudomonas aeruginosa pulmonary infections lead to increased morbidity and mortality in children with cystic fibrosis (CF). As this diagnosis is difficult to ascertain in the non-expectorating patient, the authors set out to determine if bronchoalveolar lavage (BAL)-directed therapy during the first 5 years of life leads to better outcomes than standard practice (which is therapy based on clinical features and oropharyngeal cultures).

This multicentre, randomised, parallel-group trial recruited patients between 1999 and 2005 from eight CF centres in Australia and New Zealand. Of 267 eligible infants, 36% were excluded. Patients were randomly assigned in a 1:1 ratio to receive either BAL-directed or standard therapy.

Primary outcomes at 5 years were prevalence of P aeruginosa on BAL cultures and total CF-CT score, a measure of pulmonary structural damage. Secondary outcomes were z scores for weight, height and body mass index, pulmonary function parameters, CF-CT score components, exacerbation rate, number and duration of hospitalisations for non-P aeruginosa pulmonary infections, number of episodes of P aeruginosa infection per child-year and final BAL microbiology and inflammatory indices.

This study did not find any statistically significant differences between groups for any primary or secondary outcomes, except for a reduced length of hospital stay for non-P aeruginosa respiratory-related admissions in the BAL-directed therapy group. While this may help determine clinical management, it is essential to note that the study was not powered for secondary outcomes, and CF-CT scores have yet to be validated as a clinical outcome measure.

▶ Wainwright CE, Vidmar S, Armstrong DS, et al; ACFBAL Study Investigators. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 2011;306:163–71.

View Abstract